Screen Shot 2018-08-29 at 1.23.05 PM.png

A NEW WAY OF TARGETING INFLAMMATORY DISEASE

Alivio Therapeutics is pioneering a new way to treat inflammatory diseases based on precisely tuning the immune system at the site of disease.

Alivio Therapeutics is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves tuning the immune system exclusively at the site of disease in the body, with minimal impact on the rest of the immune system. This long sought-after approach has potential to treat a range of chronic and acute inflammatory disorders including ones that would otherwise be difficult to treat.

Alivio has exclusive rights to a proprietary inflammation-targeting technology, based on the research of Dr. Karp (BWH/HMS) and Dr. Robert Langer (MIT), which is the first technology to reproducibly show the ability to target immunomodulatory compounds to inflamed tissue, which can lead to dramatic improvements in treatment efficacy with major reductions in systemic effects. The platform has been validated in multiple labs and preclinical models of inflammation, including models where the inflammation occurred in different parts of the body (e.g., the GI system, the bladder, joints, skin, etc.). The technology could potentially be used with a variety of medications (e.g., small molecules, biologics, and nucleic acids) both independently or in combination, and is designed to be administered orally or via other routes. With this platform, Alivio aims to address the dozens of conditions where inflammation is a central part of the underlying disease pathology, but where targeted and effective treatment options are lacking. 

OUR TEAM

Jeff Karp, Ph.D.
Member of the Scientific Advisory Board

Dr. Jeff Karp is a co‐founder of Alivio Therapeutics and is a Professor at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 100 peer‐reviewed papers, has given over 200 national and international ...


Robert Langer, Sc.D.
Member of the Scientific Advisory Board and Board of Directors

Dr. Robert Langer is a co-founder of Alivio Therapeutics and is known for his groundbreaking discoveries in the fields of polymer chemistry, controlled drug delivery, and tissue engineering. He is the David H. Koch Institute Professor at the Massachusetts Institute of Technology...


Michael B. Brenner, M.D.
Member of the Scientific Advisory Board

Dr. Michael Brenner is the Theodore B. Bayles Professor of Medicine at Harvard Medical School. Dr. Brenner is also the Chief of the Division of Rheumatology, Immunology, and Allergy at the Brigham and Women’s Hospital. Dr. Brenner and his laboratory have made ... 


Ivana Magovcevic‐Liebisch, Ph.D., J.D.
Member of the Board of Directors

Dr. Ivana Magovcevic-Liebisch is Executive Vice President and Chief Business Officer of Ipsen. She was previously Senior Vice President and Head of Global Business Development at Teva Pharmaceuticals. In this capacity, Ivana was responsible for the execution of transactions identified by Teva’s R&D, Global Franchises ...


Ulrich H. von Andrian, M.D., Ph.D.
Member of the Scientific Advisory Board

Dr. Ulrich von Andrian is the Mallinckrodt Professor of Immunopathology at Harvard Medical School.  Dr. von Andrian’s scientific research is focused on the regulation and function of immune cells in health and disease. Dr. von Andrian ...


Ralph Weissleder, M.D., Ph.D.
Member of the Scientific Advisory Board

Dr. Ralph Weissleder is the Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH), and Attending Clinician ...


Eric Elenko, Ph.D.
Member of the Board of Directors

Dr. Eric Elenko is a co-founder  of Alivio Therapeutics and the Chief of Research and Strategy at PureTech Health. Dr. Elenko has led the development of a number of programs, including Akili Interactive Labs, Gelesis, Karuna Pharmaceuticals and Sonde Health...


Greg Zugates, Ph.D.
vice president of research and development

Dr. Zugates is the Vice President of Research and Development for Alivio Therapeutics. He joins Alivio after spending the last 10 years at Arsenal Medical, a medical device company in Watertown, MA. During this time, he has been a lead inventor in developing Arsenal's biodegradable ... 
 


AleksHeadshot.jpg

Aleks Radovic-Moreno, PH.D.

Dr. Radovic-Moreno is a co-founder of Alivio Therapeutics and a Vice President at PureTech Health. He was previously a Research Scientist at the biotech startup Exicure (formerly AuraSense Therapeutics), where he was a lead inventor of the company's core immunotherapy ...

CAREERS

 

CONTACT US

info@aliviotherapeutics.com

Alivio Therapeutics

501 Boylston Street | Suite 6102 | Boston, MA 02116